On the Mechanism of Thrombolytic Action of Thromboxane Synthetase Inhibitors

Summary

Using our in vivo model for studying drugs which prevent deposition of thrombi or dissipate thrombi formed in extracorporeal circulation over a collagen strip superfused with arterial blood of anaesthetized and heparinized cats, we have found that dazoxiben - a thromboxane synthetase inhibitor - possesses not only antithrombotic but also thrombolytic potency in vivo (ED₅₀ = 3.8 mg/kg i.v.). The thrombolytic potency of dazoxiben was antagonized by aspirin at a dose of 50 mg/kg i.v. Moreover, dazoxiben stimulated the generation of prostacyclin in isolated rat aortic slices incubated in platelet rich plasma, but not in platelet poor plasma. It is suggested that the thrombolytic potency of thromboxane synthetase inhibitors after their systemic administration is associated with the release of prostacyclin and/or prostacyclin-stable metabolites by the vascular endothelium owing to feeding of prostacyclin synthetase with prostaglandin endoperoxides acumulated in platelets following the inhibition of thromboxane synthetase.

Keywords

Dazoxiben - Inhibitors of thromboxane synthetase - Thrombolysis - Prostaglandin endoperoxides

• References

• 1 Moncada S, Bunting S, Mullane K, Thorogood P, Vane JR, Raz A, Needleman P. Imidazole: A selective inhibitor of thromboxane synthetase. Prostaglandins 1977; 13: 611
• 2 Blackwell GJ, Flower RJ, Russel-Smith N, Salmon JA, Thorogood PB, Vane JR. 1-N-butylimidazole: a potent and selective inhibitor of thromboxane synthetase. Br J Pharmacol 1978; 64: 436 P
• 3 Tyler HM, Saxton CA, Parry MJ. Administration to man of UK-37 248 01, a selective inhibitor of thromboxane synthetase. Lancet 1981; 2: 629
• 4 Heptinstall S, Bevan J, Cockhill S R, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thrombosis Res 1980; 20: 129
• 5 Gryglewski RJ, Korbut R, Ocetkiewicz A, Stachura J. In vivo method for quantitation of anti-platelet potency of drugs. Naunyn-Schmiedeberg’s Arch Pharmacol 1978; 302: 25
• 6 Gryglewski RJ, Korbut R, Ocetkiewicz A. De-aggregatory action of prostacyclin in vivo and its enhancement by theophylline. Prostaglandins 1978; 15: 637
• 7 Gryglewski RJ, Korbut R, Ocetkiewicz A. Reversal of platelet aggregation by prostacyclin. Pharmacol Res Commun 1978; 10: 185
• 8 Gryglewski RJ, Korbut R, Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 1978; 273: 765
• 9 Gryglewski RJ, Korbut R, Radomski M. Transformation of prostacyclin by horse platelet cytosole to a stable metabolite which has fibrinolytic activity in vitro. In: USA-Poland Symposium Cardiovascular Disease, June 1984. U.S.Department of Health and Human Services (ed). NIH Publication No 86: 1986: 9
• 10 Korbut R, Byrska-Danek A, Gryglewski RJ. Fibrinolytic activity of 6-keto-prostaglandin E₁ . Thromb Haemostas 1983; 50: 893
• 11 Zmuda A, Dembinska-Kiec A, Chytkowski A, Gryglewski RJ. Experimental atherosclerosis in rabbit. Platelet aggregability, thromboxane A2 generation and anti-aggregatorv potency of prostacyclin. Prostaglandins 1977; 14-1035
• 12 Born G VR, Cross MY. The aggregation of blood platelets. J Physiol (London) 1963; 168: 178
• 13 Splawiriski J, Wojtaszek B, Marcinkiewicz E. Bioassay of thromboxane A2 with the help of guinea pig parenchyma strips. In: Prostaglandins and Thromboxanes. Forster W. (ed). VEB Gustav Fischer Verlag; Jean: 1980
• 14 Malmsten C. Some biological effect of prostaglandin endoperoxide analogues. Life Sci 1976; 18: 169
• 15 Bunting S, Gryglewski RJ, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (Prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897
• 16 Korbut R, Moncada S. Prostacyclin (PG12) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with antithrombotic therapy. Thromb Res 1978; 13: 489
• 17 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Nat Adv Sci 1975; 1975: 2994
• 18 Samuelsson B. Prostaglandin endoperoxides and thromboxanes. Role in platelets and vascular and respiratory smooth muscle. Acta Biol Med Germ 1976; 35: 1055
• 19 Wong PY-K, Malik KU, Desiderio DM, McGiff JC, Sun FF. Hepatic metabolism of prostacyclin (PGI2) in the rabbit: formation of a potent novel inhibitor of platelet aggregation. Biochem Biophys Res Conimun 1980; 93: 486
• 20 Flower RJ, Heuno HS, Cushman DW. Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase system of bovine seminal vesicles. Prostaglandins 1973; 4: 325